
Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Drugs In Development, 2022, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.
Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dengue Fever - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 10, 39, 20 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 12 and 15 molecules, respectively.
Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Drugs In Development, 2022, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.
Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dengue Fever - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 10, 39, 20 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 12 and 15 molecules, respectively.
Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
180 Pages
- Introduction
- Global Markets Direct Report Coverage
- Dengue Fever – Overview
- Dengue Fever – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Dengue Fever – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Dengue Fever – Companies Involved in Therapeutics Development
- 60 Degrees Pharmaceuticals LLC
- Abhelix LLC
- Abivax SA
- AbViro LLC
- Acer Therapeutics Inc
- Atea Pharmaceuticals Inc
- Avida Biotech SL
- Biological Mimetics Inc
- BioNet-Asia Co Ltd
- Biotron Ltd
- Bugworks Research Inc
- Cidara Therapeutics Inc
- Codagenix Inc
- Decoy Therapeutics Inc
- Emergex Vaccines Holding Ltd
- Ennaid Therapeutics LLC
- Etna Biotech Srl
- Excivion Ltd
- Exopharm Ltd
- Globavir Biosciences Inc
- Greffex Inc
- Hercules Pharmaceuticals BV
- HSRx Group
- ImmuneMed Inc
- Immunotope Inc
- Imutex Ltd
- Indian Immunologicals Ltd
- Inovio Pharmaceuticals Inc
- Integral Molecular Inc
- Island Pharmaceuticals Ltd
- Johnson & Johnson
- KARE Biosciences Inc
- KinoPharma Inc
- KM Biologics Co Ltd
- Mabloc LLC
- Macrophage Therapeutics Inc
- Medigen Inc
- Meletios Therapeutics SAS
- Moleculin Biotech Inc
- Najit Technologies Inc
- NanoViricides Inc
- Novartis AG
- Panacea Biotec Ltd
- Plex Pharmaceuticals Inc
- ProtInhi BV
- ReVacc Biotech
- Riboscience LLC
- Seagull BioSolutions Pvt Ltd
- Serum Institute of India Pvt Ltd
- Shionogi & Co Ltd
- Sun Pharma Advanced Research Company Ltd
- Takeda Pharmaceutical Co Ltd
- TechnoVax Inc
- TenGen Biomedical Co
- Theravectys SA
- TrippBio Inc
- Uvax Bio LLC
- Vir Biotechnology Inc
- Virocovax
- Visterra Inc
- VLP Therapeutics LLC
- Xenothera SAS
- Zucero Therapeutics Ltd
- Zydus Lifesciences Ltd
- Dengue Fever – Drug Profiles
- (dengue + zika) (pentavalent) vaccine – Drug Profile
- 33D2 Ab – Drug Profile
- ABT-001 – Drug Profile
- ABX-196 – Drug Profile
- ABX-220 – Drug Profile
- AGS-v – Drug Profile
- AGS-v PLUS – Drug Profile
- Anti-Viral Fusion Inhibitor Peptide – Drug Profile
- Antibodies to Inhibit Envelope Protein for Dengue Fever and Zika Virus Infection – Drug Profile
- Antisense RNAi Oligonucleotide for Dengue Fever – Drug Profile
- Antiviral Therapies – Drug Profile
- AT-752 – Drug Profile
- AV-1 – Drug Profile
- Bi-specific Monoclonal Antibody for Dengue – Drug Profile
- Biologics to Antagonize TLR4 for Dengue Fever – Drug Profile
- CDX-DENV – Drug Profile
- celgosivir hydrochloride – Drug Profile
- dengue (tetravalent) vaccine – Drug Profile
- dengue (tetravalent) vaccine 4 – Drug Profile
- dengue (virus like particle) vaccine – Drug Profile
- dengue + Zika virus vaccine – Drug Profile
- dengue [serotype 1,2,3,4] (tetravalent) vaccine – Drug Profile
- dengue [serotype 2] (monovalent) vaccine – Drug Profile
- dengue [serotype 3] (monovalent) vaccine – Drug Profile
- dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine – Drug Profile
- dengue [serotypes 1, 2, 3, 4] (tetravalent) virus like particle vaccine – Drug Profile
- dengue [serotypes 1, 2, 3, 4] (tetravalent, virus like particle) vaccine – Drug Profile
- dengue [serotypes 1, 3, 4] (trivalent) vaccine – Drug Profile
- Dengue Antibody – Drug Profile
- Dengue Monoclonals – Drug Profile
- dengue vaccine – Drug Profile
- Dengue Viruses – Drug Profile
- dengue-Zika (bivalent) vaccine – Drug Profile
- Dengusiil – Drug Profile
- emetine hydrochloride – Drug Profile
- EMX-001 – Drug Profile
- ETX-101 – Drug Profile
- ETxR-12 – Drug Profile
- EYU-688 – Drug Profile
- Flavivirus Infections (Zika West Nile and Dengue Virus) – Drug Profile
- GBV-006 – Drug Profile
- Gene Therapy for Dengue Fever – Drug Profile
- GREDEN/V1-4 – Drug Profile
- HP-163 – Drug Profile
- HSRx-431 – Drug Profile
- IMV-01 – Drug Profile
- infectious disease vaccine – Drug Profile
- INOA-002 – Drug Profile
- ISLA-101 – Drug Profile
- JNJ-1802 – Drug Profile
- KD-382 – Drug Profile
- lucidone – Drug Profile
- MLT-103 – Drug Profile
- MLT-301 – Drug Profile
- modipafant – Drug Profile
- Monoclonal Antibodies for Dengue – Drug Profile
- Monoclonal Antibodies for Dengue Fever – Drug Profile
- Monoclonal Antibodies to Target Virion, prM and E Proteins for Dengue – Drug Profile
- Monoclonal Antibody Conjugate for Dengue Fever and Zika Virus Infections – Drug Profile
- Monoclonal Antibody for Dengue Fever – Drug Profile
- MT-2002 – Drug Profile
- MTX-113 – Drug Profile
- Pan Flavivirus T-cell Vaccine – Drug Profile
- PepGNP-Dengue – Drug Profile
- pixatimod – Drug Profile
- Polysaccharides for Viral Infections – Drug Profile
- ramatroban – Drug Profile
- Recombinant Peptide to Inhibit Dengue Protease for Dengue – Drug Profile
- REVC-150 – Drug Profile
- SBPL-0200 – Drug Profile
- Small Molecule for Dengue Fever – Drug Profile
- Small Molecule for Dengue Fever and Zika Virus Infections – Drug Profile
- Small Molecule to Inhibit NS3 Protease for Dengue – Drug Profile
- Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections – Drug Profile
- Small Molecules for Dengue Fever and Zika Virus Infection – Drug Profile
- Small Molecules for Infectious Disease – Drug Profile
- Small Molecules for Viral Infections – Drug Profile
- Small Molecules to Antagonize TLR4 for Dengue Fever – Drug Profile
- Small Molecules to Inhibit Envelope Protein for Dengue – Drug Profile
- Small Molecules to Inhibit Flavivirus Serine Protease for Viral Infections – Drug Profile
- Small Molecules to Inhibit M Protein for Dengue – Drug Profile
- Small Molecules to Inhibit NS2B-NS3 Protease for Dengue, West Nile Virus and Zika Infections – Drug Profile
- Small Molecules to Inhibit NS4B for Dengue Fever – Drug Profile
- Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections – Drug Profile
- Synthetic Peptides to Inhibit NS2B and NS3 for Dengue Fever – Drug Profile
- TD-214 – Drug Profile
- TV-003 – Drug Profile
- TVX-005 – Drug Profile
- VIROX-1 – Drug Profile
- VIS-513 – Drug Profile
- VSRD-DENV – Drug Profile
- WLBU-2 – Drug Profile
- WP-1096 – Drug Profile
- WP-1097 – Drug Profile
- XAV-3 – Drug Profile
- ZRCNB-3224 – Drug Profile
- Dengue Fever – Dormant Projects
- Dengue Fever – Discontinued Products
- Dengue Fever – Product Development Milestones
- Featured News & Press Releases
- Dec 09, 2022: EC grants marketing authorisation for Takeda’s dengue vaccine
- Dec 05, 2022: ISLA-101 trial update and investor presentation
- Nov 22, 2022: Takeda’s Biologics license application (BLA) for dengue vaccine candidate (TAK-003) granted priority review by U.S. Food and Drug Administration
- Nov 16, 2022: Island Pharmaceuticals granted key Canadian patent for ISLA-101
- Nov 15, 2022: Island to present at World Antiviral Congress 2022
- Nov 14, 2022: Island Pharmaceuticals : Positive analytical results for ISLA-101 capsules
- Nov 03, 2022: Atea Pharmaceuticals presents favorable AT-752 phase 1 data for treatment of dengue fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
- Oct 28, 2022: ISLA-101 manufacturing progress
- Oct 14, 2022: Takeda receives positive CHMP opinion recommending approval of dengue vaccine candidate in EU and dengue-endemic countries
- Sep 26, 2022: Atea Pharmaceuticals announces U.S. FDA fast track designation granted to AT-752 for treatment of dengue
- Aug 22, 2022: Takeda’s QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) approved in Indonesia for use regardless of prior dengue exposure
- Aug 17, 2022: Codagenix announces award with the US Department of Defense for development of balanced, tetravalent dengue vaccine
- Jun 15, 2022: Island Pharmaceuticals ISLA-101 announced manufacturing and timeline update
- Jun 09, 2022: Takeda’s dengue vaccine candidate provides continued protection against dengue fever through 4.5 years in pivotal clinical trial
- Apr 18, 2022: Emergex provides an update on first-in-human studies of its novel dengue fever
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Dengue Fever, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Universities/Institutes, 2022
- Table 7: Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022
- Table 9: Products under Development by Companies, 2022 (Contd..1)
- Table 10: Products under Development by Companies, 2022 (Contd..2)
- Table 11: Products under Development by Companies, 2022 (Contd..3)
- Table 12: Products under Development by Companies, 2022 (Contd..4)
- Table 13: Products under Development by Universities/Institutes, 2022
- Table 14: Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 15: Number of Products by Stage and Target, 2022
- Table 16: Number of Products by Stage and Mechanism of Action, 2022
- Table 17: Number of Products by Stage and Route of Administration, 2022
- Table 18: Number of Products by Stage and Molecule Type, 2022
- Table 19: Dengue Fever – Pipeline by 60 Degrees Pharmaceuticals LLC, 2022
- Table 20: Dengue Fever – Pipeline by Abhelix LLC, 2022
- Table 21: Dengue Fever – Pipeline by Abivax SA, 2022
- Table 22: Dengue Fever – Pipeline by AbViro LLC, 2022
- Table 23: Dengue Fever – Pipeline by Acer Therapeutics Inc, 2022
- Table 24: Dengue Fever – Pipeline by Atea Pharmaceuticals Inc, 2022
- Table 25: Dengue Fever – Pipeline by Avida Biotech SL, 2022
- Table 26: Dengue Fever – Pipeline by Biological Mimetics Inc, 2022
- Table 27: Dengue Fever – Pipeline by BioNet-Asia Co Ltd, 2022
- Table 28: Dengue Fever – Pipeline by Biotron Ltd, 2022
- Table 29: Dengue Fever – Pipeline by Bugworks Research Inc, 2022
- Table 30: Dengue Fever – Pipeline by Cidara Therapeutics Inc, 2022
- Table 31: Dengue Fever – Pipeline by Codagenix Inc, 2022
- Table 32: Dengue Fever – Pipeline by Decoy Therapeutics Inc, 2022
- Table 33: Dengue Fever – Pipeline by Emergex Vaccines Holding Ltd, 2022
- Table 34: Dengue Fever – Pipeline by Ennaid Therapeutics LLC, 2022
- Table 35: Dengue Fever – Pipeline by Etna Biotech Srl, 2022
- Table 36: Dengue Fever – Pipeline by Excivion Ltd, 2022
- Table 37: Dengue Fever – Pipeline by Exopharm Ltd, 2022
- Table 38: Dengue Fever – Pipeline by Globavir Biosciences Inc, 2022
- Table 39: Dengue Fever – Pipeline by Greffex Inc, 2022
- Table 40: Dengue Fever – Pipeline by Hercules Pharmaceuticals BV, 2022
- Table 41: Dengue Fever – Pipeline by HSRx Group, 2022
- Table 42: Dengue Fever – Pipeline by ImmuneMed Inc, 2022
- Table 43: Dengue Fever – Pipeline by Immunotope Inc, 2022
- Table 44: Dengue Fever – Pipeline by Imutex Ltd, 2022
- Table 45: Dengue Fever – Pipeline by Indian Immunologicals Ltd, 2022
- Table 46: Dengue Fever – Pipeline by Inovio Pharmaceuticals Inc, 2022
- Table 47: Dengue Fever – Pipeline by Integral Molecular Inc, 2022
- Table 48: Dengue Fever – Pipeline by Island Pharmaceuticals Ltd, 2022
- Table 49: Dengue Fever – Pipeline by Johnson & Johnson, 2022
- Table 50: Dengue Fever – Pipeline by KARE Biosciences Inc, 2022
- Table 51: Dengue Fever – Pipeline by KinoPharma Inc, 2022
- Table 52: Dengue Fever – Pipeline by KM Biologics Co Ltd, 2022
- Table 53: Dengue Fever – Pipeline by Mabloc LLC, 2022
- Table 54: Dengue Fever – Pipeline by Macrophage Therapeutics Inc, 2022
- Table 55: Dengue Fever – Pipeline by Medigen Inc, 2022
- Table 56: Dengue Fever – Pipeline by Meletios Therapeutics SAS, 2022
- Table 57: Dengue Fever – Pipeline by Moleculin Biotech Inc, 2022
- Table 58: Dengue Fever – Pipeline by Najit Technologies Inc, 2022
- Table 59: Dengue Fever – Pipeline by NanoViricides Inc, 2022
- Table 60: Dengue Fever – Pipeline by Novartis AG, 2022
- Table 61: Dengue Fever – Pipeline by Panacea Biotec Ltd, 2022
- Table 62: Dengue Fever – Pipeline by Plex Pharmaceuticals Inc, 2022
- Table 63: Dengue Fever – Pipeline by ProtInhi BV, 2022
- Table 64: Dengue Fever – Pipeline by ReVacc Biotech, 2022
- Table 65: Dengue Fever – Pipeline by Riboscience LLC, 2022
- Table 66: Dengue Fever – Pipeline by Seagull BioSolutions Pvt Ltd, 2022
- Table 67: Dengue Fever – Pipeline by Serum Institute of India Pvt Ltd, 2022
- Table 68: Dengue Fever – Pipeline by Shionogi & Co Ltd, 2022
- Table 69: Dengue Fever – Pipeline by Sun Pharma Advanced Research Company Ltd, 2022
- Table 70: Dengue Fever – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 71: Dengue Fever – Pipeline by TechnoVax Inc, 2022
- Table 72: Dengue Fever – Pipeline by TenGen Biomedical Co, 2022
- Table 73: Dengue Fever – Pipeline by Theravectys SA, 2022
- Table 74: Dengue Fever – Pipeline by TrippBio Inc, 2022
- Table 75: Dengue Fever – Pipeline by Uvax Bio LLC, 2022
- Table 76: Dengue Fever – Pipeline by Vir Biotechnology Inc, 2022
- Table 77: Dengue Fever – Pipeline by Virocovax, 2022
- Table 78: Dengue Fever – Pipeline by Visterra Inc, 2022
- Table 79: Dengue Fever – Pipeline by VLP Therapeutics LLC, 2022
- Table 80: Dengue Fever – Pipeline by Xenothera SAS, 2022
- Table 81: Dengue Fever – Pipeline by Zucero Therapeutics Ltd, 2022
- Table 82: Dengue Fever – Pipeline by Zydus Lifesciences Ltd, 2022
- Table 83: Dengue Fever – Dormant Projects, 2022
- Table 84: Dengue Fever – Dormant Projects, 2022 (Contd..1)
- Table 85: Dengue Fever – Dormant Projects, 2022 (Contd..2)
- Table 86: Dengue Fever – Dormant Projects, 2022 (Contd..3)
- Table 87: Dengue Fever – Dormant Projects, 2022 (Contd..4)
- Table 88: Dengue Fever – Dormant Projects, 2022 (Contd..5)
- Table 89: Dengue Fever – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Dengue Fever, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.